Ancillary Events

Industry Satellite Symposium

Thursday, February 27, 2020
5:15 p.m. - 5:45 p.m. - Registration and Dinner
5:45 p.m. - 7:15 p.m. - Symposium
Trailblazer AB

To register or learn more, visit PeerView.com/HNCLive20.

Multimodal Head and Neck Cancer Care Meets the Immunotherapy Era: A Look at the Changing Nature of Multidisciplinary Collaboration and Integrated Treatment Strategies

Key Reasons to Attend

• Get the latest lessons from the evidence on immunotherapy across the spectrum of head and neck cancer (HNC).
• Hear experts debate the role of immunotherapy as a new upfront standard in recurrent/metastatic HNC.
• Find out about important, ongoing studies testing immune agents with surgery and radiotherapy.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute Inc., and PVI, PeerView Institute for Medical Education. The Medical Learning Institute Inc., is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant from Merck & Co., Inc.

---

Industry-Expert Theaters

Nanobiotix Industry-Expert Theater

Thursday, February 27, 2020
 5:30 p.m. - 7:00 p.m.
 Trailblazer DE

Space is limited, so please register at www.nanobiotix.live

Disrupting the Limits of Radiation Therapy with Nano

Locally advanced head and neck cancer patients that are ineligible for cisplatin face a variety of unmet needs, and disruptive innovation in radiation therapy could provide enormous benefits for this population.

Learn how Nanobiotix is pioneering the field with its first-in-class radioenhancer NBTXR3, how current clinical results are showing promise for this new treatment, and how a new phase III registration trial seeks to bring these benefits to patients in the U.S. and EU.

During the session, leading medical experts will discuss the company and its first-in-class radioenhancer NBTXR3 — an aqueous suspensions of crystalline hafnium oxide that, after intramural injection prior to a patient’s first radiation therapy session, increases the energy deposit from ionizing radiation within the cell without increasing the dose in surrounding healthy tissues.

Pr. Christophe Le Tourneau of the Curie Institute, who has extensive experience with NBTXR3 as the principal investigator of Study 102 (phase I evaluating NBTXR3 activated by radiation therapy in elderly patients ineligible for cisplatin), will describe promising data from the study along with plans to leverage real world evidence to demonstrate the efficacy of the product.

Dr. Sue Yom of UCSF will continue by discussing FLOW-312, the upcoming phase III registration trial in the US and EU evaluating NBTXR3 activated by radiation therapy in elderly patients with locally advanced disease that are ineligible for cisplatin. Dr. Yom will discuss rationale and trial design for the study.

The session with conclude with a round table discussion of the potential of NBTXR3 to significantly improve outcomes for patients with Head and Neck cancer around the world.

Hors d’oeuvres, coffee and soft drinks will be provided.

---

Merck and Co. Inc., Industry-Expert Theater

Friday, February 28, 2020
 6:00 p.m. - 7:00 p.m.
 Trailblazer C

Advances in First-line Recurrent or Metastatic HNSCC Patient Treatment

Learning Objectives

• Identify appropriate patients for a 1L treatment option with R/M HNSCC
• Review the efficacy and safety data supporting the use of a 1L option for treating patients with R/M HNSCC 
• Discuss the management of a 1L treatment option for patients with R/M HNSCC

Speaker Bio: Krzysztof Misiukiewicz, MD, MSCR, is Associate Professor at Mount Sinai School of Medicine, Department of Medicine, Div. of Hematology/Oncology and Clinical Director for the Center for Personalized Cancer Therapeutics and Chairman of the Oncology Pharmacy and Therapeutics Committee at Mount Sinai Hospital. He attended Medical Academy in Wroclaw, Poland and completed his residency in internal medicine at St. Barnabas Medical Center, followed by fellowship training in hematology and oncology at Mt. Sinai. He is board certified in internal medicine, hematology and medical oncology. Dr. Misiukiewicz's clinical expertise includes medical management of head and neck and thyroid cancer. His research investigates new ways to combine traditional treatments such as chemotherapy and radiotherapy with targeted agents and immunotherapy and he is co-author or author of medical textbook chapters and articles in peer-reviewed journals including Annals of Medicine and Journal of Clinical Oncology.

The Program is not for CE/CME credit and, consistent with the PhRMA Code on Interactions with Healthcare Professionals effective January 2009, that the Program is sponsored by and presented on behalf of Merck. The information presented will be consistent with FDA guidelines.
 

---

Regeneron and Sanofi Industry-Expert Theater

Friday, February 28, 2020
 5:30 p.m. - 7:15 p.m.
 Trailblazer AB

Come discover a systemic treatment option for patients with advanced Cutaneous Squamous Cell Carcinoma (CSCC)

View the speaker bio.

Cutaneous squamous cell carcinoma (CSCC) is one of the most common cancers worldwide and continues to increase in incidence. Advanced CSCC can be particularly aggressive and has historically had limited treatment options. Come learn about the mechanism of action, clinical efficacy and safety data, patient eligibility, and dosage and administration of an FDA approved treatment option for appropriate patients suffering from advanced CSCC.